Adjunctive corticosteroid therapy for pneumocystis carinii pneumonia in aids: A randomized european multicenter open label study

Thyge L. Nielsen*, Jan K.M.Eeftinck Schattenkerk, Birgitte N. Jensen, Jens D. Lundgren, Jan Gerstoft, Reindert P. Van Steenwijk, Kirsten Bentsen, P. H.Jos Frissen, Johs Gaub, Marianne Orholm, John Erik Hansen, Lars Mathiesen, Peter Skinhøj, Sven A. Danner, Jens O. Nielsen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Fifty-nine human immunodeficiency virus type-1-infected patients with a microscopically proven first episode of moderate to severe Pneumocystis carinii pneumonia (PCP) were enrolled into a randomized European multi-center study. The effect of adjunctive corticosteroid (CS) therapy was assessed on (a) survival to discharge, (b) need for mechanical ventilation, and (c) survival at day 90. CS was given within 24 h of standard therapy as intravenous methylprednisolone 2 mg/kg body weight daily for 10 days. All patients received cotrimoxazole as standard treatment. Inclusion criteria were a Pao2 <9.0 kPa (67.5 mm Hg) and/or a PaCo2 <4.0 kPa (30.0 mm Hg) while breathing room air. During the acute episode of PCP, 9 (31%) of the 29 control patients died versus 3 (10%) of the 30 CS patients; p = 0.01. Mechanical ventilation was necessary in 15 patients; 12 (41%) in the control group and 3 (10%) in the CS group; p = 0.01. The 90-day survival was 69% in controls versus 87% in CS patients; p = 0.07. Based on these data we conclude that adjunctive CS therapy for moderate to severe PCP in AIDS patients reduces the acute mortality and the need for mechanical ventilation.

Original languageEnglish
Pages (from-to)726-731
Number of pages6
JournalJournal of Acquired Immune Deficiency Syndromes
Volume5
Issue number7
Publication statusPublished - Jul 1992

Cite this